BIOLASE, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Redeemable Preferred Stock and Stockholders' Equity - Additional Information (Detail)

Redeemable Preferred Stock and Stockholders' Equity - Additional Information (Detail) - USD ($)					1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 23, 2020	Jul. 23, 2020	Jul. 22, 2020	Jun. 10, 2020	Jul. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Dec. 31, 2019
Temporary Equity And Stockholders Equity [Line Items]
Common stock, shares authorized						180,000,000		180,000,000			40,000,000
Series F Preferred stock, shares issued						1,000		1,000			0
Common stock value						$ 93,000		$ 93,000			$ 31,000
Proceeds from offering, net of underwriting discounts and commissions			$ 16,100,000		$ 8,000,000
Warrants issued in connection with debt instruments								$ 67,000	$ 209,000
Expected term (years)							6 years 1 month 6 days	5 years 6 months	6 years 1 month 6 days
Volatility							85.40%	102.80%	85.40%
Risk-free interest rate							2.60%	0.37%	2.60%
Change in fair value of warrants								$ (5,850,000)
Issuance costs for common stock warrants								1,640,000
Deemed dividend on convertible preferred stock						$ 17,378,000		$ 17,378,000
Series E Preferred stock, shares authorized						1,000,000		1,000,000			1,000,000
Series E Preferred stock, par value						$ 0.001		$ 0.001			$ 0.001
Series E Preferred stock, shares issued						0		0			70,000
Series E Preferred stock, shares outstanding						0		0			70,000
Compensation expense related to stock options						$ 800,000	$ 800,000	$ 2,400,000	$ 1,900,000
Total unrecognized compensation expense						$ 1,400,000		$ 1,400,000
Unrecognized share based compensation expense to be recognized over weighted-average period						1 year 2 months 12 days
Warrant expiration date				Jun. 10, 2025
Proceeds from offering				$ 6,900,000
Combined purchase price of share and warrant				$ 0.64
Other offering expenses				$ 700,000
Outstanding stock options, RSUs and warrants excluded from diluted loss per share						67,200,000	5,600,000	67,200,000	5,600,000
June 2020 Warrants
Temporary Equity And Stockholders Equity [Line Items]
Proceeds of common stock and warrants								$ 6,200,000
Exercise price of warrants						$ 0.42		$ 0.42
Expected term (years)								5 years
Closing price of common stock								$ 0.54
Volatility								109.80%
Risk-free interest rate								0.45%
Dividend yield								0.00%
Allocation to preferred stock and warrants before issuance costs								$ 3,000,000
Allocation to common stock and warrants before issuance costs								$ 3,900,000
Restricted Stock Units (RSUs)
Temporary Equity And Stockholders Equity [Line Items]
Granted								2.9
Cancelled RSU due to non achievement of performance targets								1.0
2002 Stock Incentive Plan
Temporary Equity And Stockholders Equity [Line Items]
Common stock authorized for issuance						3,100,000		3,100,000
Common stock issued pursuant to options exercised								1,000,000
Options and restricted stock units outstanding						1,100,000		1,100,000
Options available for future grants						0		0
2018 Long-Term Incentive Plan
Temporary Equity And Stockholders Equity [Line Items]
Common stock authorized for issuance						12,200,000		12,200,000
Options and restricted stock units outstanding						5,300,000		5,300,000
Options available for future grants						3,800,000		3,800,000
Maximum
Temporary Equity And Stockholders Equity [Line Items]
Series E Preferred stock, shares authorized											1,000,000
Private Placement
Temporary Equity And Stockholders Equity [Line Items]
Exercise price of warrants				$ 0.515
Common stock offered				10,800,000
July 2020 Warrants
Temporary Equity And Stockholders Equity [Line Items]
Warrant issued	45,000,000	45,000,000
Change in fair value of warrants								$ (5,800,000)
Issuance costs for common stock warrants						$ 1,600,000		1,600,000
July 2020 Warrants \| Rights Offering
Temporary Equity And Stockholders Equity [Line Items]
Warrant issued	45,000,000	45,000,000
Allocated to the warrants based upon fair values	$ 15,300,000	$ 15,300,000
Exercise price of warrants	$ 0.40	$ 0.40
Allocation to preferred stock and warrants before issuance costs								$ 15,300,000
Series F Convertible Preferred Stock and July 2020 Warrants
Temporary Equity And Stockholders Equity [Line Items]
Deemed dividend on convertible preferred stock						$ 14,700,000
Series F Convertible Preferred Stock and July 2020 Warrants \| Rights Offering
Temporary Equity And Stockholders Equity [Line Items]
Exercise price of warrants						$ 0.34		$ 0.34
Expected term (years)								5 years
Closing price of common stock								$ 0.44
Volatility								109.80%
Risk-free interest rate								0.27%
Dividend yield								0.00%
Series F Convertible Preferred Stock
Temporary Equity And Stockholders Equity [Line Items]
Sale of common stock, shares								17,000
Series F Preferred Stock and July Two Thousand Twenty Amendment \| Rights Offering
Temporary Equity And Stockholders Equity [Line Items]
Exercise price of warrants						$ 0.21		$ 0.21
Expected term (years)								5 years
Closing price of common stock								$ 0.28
Volatility								109.50%
Risk-free interest rate								0.26%
Dividend yield								0.00%
Series F Convertible Preferred Stock
Temporary Equity And Stockholders Equity [Line Items]
Series F Preferred stock, shares issued	18,000	18,000
Common stock value						$ 1,000		$ 1,000
Conversion price								$ 0.40
Proceeds from offering, net of underwriting discounts and commissions								$ 18,000,000
Broker fees and related expenses								1,900,000
Proceeds of common stock and warrants	$ 18,000,000
Warrants issued in connection with debt instruments						$ 2,700,000		15,300,000
Deemed dividend on convertible preferred stock		$ 2,700,000						14,700,000
Series E Preferred stock, shares authorized											18,000
Series E Preferred stock, par value											$ 0.001
Series F Convertible Preferred Stock \| Rights Offering
Temporary Equity And Stockholders Equity [Line Items]
Proceeds allocated to the warrants based upon fair values	$ 2,700,000
Sale of common stock, shares	18,000
Preferred stock par value	$ 0.001	$ 0.001
Allocation to preferred stock and warrants before issuance costs								$ 2,700,000
Series E Convertible Preferred Stock
Temporary Equity And Stockholders Equity [Line Items]
Series E Preferred stock, shares authorized											69,565
Series E Preferred stock, par value											$ 0.001
Series E Preferred stock, shares issued						0		0			69,565
Series E Preferred stock, shares outstanding						0		0			69,565
Series E Convertible Preferred Stock \| Private Placement
Temporary Equity And Stockholders Equity [Line Items]
Temporary equity numbers of shares sold										69,565
Conversion Of Preferred Stock Into Common Stock						6,956,500		6,956,500
Temporary equity net proceeds from conversion to common stock						$ 4,000,000		$ 4,000,000